Burn Validation Study Success
The Burn Validation Study, utilizing over 340 billion clinically validated data points, demonstrated the superior performance of Spectral AI's DeepView technology in predicting burn wound healing. This study will be part of the FDA De Novo submission.
Increased Revenue and Improved Financials
Research and development revenue for the first quarter rose 6% to $6.7 million, and gross margin increased to 47.2%. The company reported a net income of $2.9 million compared to a net loss of $3.2 million in the previous year.
Successful Financing Efforts
Spectral AI completed a debt financing agreement of up to $15 million and raised approximately $2.7 million in equity financing. Cash and cash equivalents increased to $14.1 million from $5.2 million.
Reduced Operating Loss
Operating loss for the first quarter of 2025 was reduced to $896,000 from $2.1 million in the first quarter of 2024 due to cost-cutting measures.
Progress in MTEC Development
Development of the DeepView System handheld device, DeepView Snapshot M, is on track with two fully functional prototypes assembled.